Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-17T06:14:14.530Z Has data issue: false hasContentIssue false

Global cognitive functioning in TRD and non-TRD patients: longitudinal real-world evidence from the PROMPT study

Published online by Cambridge University Press:  31 July 2026

V. T. H. Wahner*
Affiliation:
Department of Psychiatry, University of Münster, Münster
S. Jörgens
Affiliation:
Department of Psychiatry, University of Münster, MünsterDepartment Hamm 2, Hochschule Hamm-Lippstadt, Hamm, Germany
B. T. Baune
Affiliation:
Department of Psychiatry, University of Münster, MünsterDepartment of Psychiatry, University of MelbourneFlorey Institute of Neuroscience and Mental Health, Parkville, Australia
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.
Introduction

The exact role of cognitive functioning (CF) and impairment in treatment-resistant depression (TRD) is not well understood. In particular, the lack of longitudinal and comparative data with non-TRD patients represents a major gap in the current literature.

Objectives

This study sought to compare 12-week trajectories of global CF between TRD and non-TRD patients in a real-world setting.

Methods

This prospective observational study included 146 inpatients with major depressive disorder (MDD) who were assessed with a standardized cognitive test battery (BAC-A) and structured clinical interviews at baseline, week 8, and week 12. Fifty-four patients (mean age = 48.5±15.5; 48% female) met the criteria for TRD, defined as nonresponse to at least two antidepressant regimens during the current episode, and were compared with ninety-two non-TRD patients (mean age = 33.9±12.8; 50% female). Composite cognitive z-scores (age- and sex-adjusted) were analysed using linear mixed-effects models to examine the effects of group, time and their interaction. In a second step, the model was adjusted for symptom severity (MADRS scores), recurrence, years of education, current medication (benzodiazepines, antipsychotics) and psychiatric comorbidities (anxiety disorders, personality disorders).

Results

Global CF improved significantly over 12 weeks (β = 0.29, p < .001). The TRD group showed lower baseline CF (β = -0.45, p = .032). This group effect was no longer significant after adjustment for clinical covariates. Higher education predicted better CF (β = 0.12, p < .001), whereas antipsychotic use was associated with poorer CF (β = -0.74, p < .001). The non-significant group × time interaction indicated similar trajectories between groups. Random-effects variances (intercept = 1.05; slope = 0.00) suggested substantial between-subject variability at baseline and parallel improvement trajectories. Figure 1 depicts group mean trajectories of global CF over 12 weeks.Image 1:

Line graph showing neuropsychological composite Z-scores for non-T R D and T R D groups over 12 weeks. See long description.

Conclusions

Observed differences in global CF between TRD and non-TRD patients appear to reflect underlying clinical characteristics rather than treatment resistance per se. Future studies should investigate group differences at the domain level and account for substantial between-subject variability in their analyses.

Disclosure of Interest

V. Wahner: None Declared, S. Jörgens: None Declared, B. Baune Consultant of: BTB received speaker/consultation fees from: AstraZeneca, Lundbeck, Pfizer, Takeda, Servier, Bristol Myers Squibb, Otsuka, LivaNova, Boehringer-Ingelheim, Biogen and Janssen-Cilag.

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.